Structural insights into Resveratrol's antagonist and partial agonist actions on estrogen receptor alpha

BMC Structural Biology

Volumn 13, Issue 1, 2013, Pages

  Chakraborty, Sandipan ^a,b   Levenson, Anait S ^c   Biswas, Pradip K ^a  

^a TOUGALOO COLLEGE   (United States)

^b Saroj Mohan Institute of Technology   (India)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Agonist; Antagonist; Estrogen Receptor; Helix 12; Hydrogen bonding; Molecular dynamics simulation; Phytoestrogen; Resveratrol

Indexed keywords

AFIMOXIFENE; ANTIESTROGEN; DIETHYLSTILBESTROL; DIMER; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; HYDROGEN; MONOMER; PARTIAL AGONIST; RESVERATROL;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; DIMERIZATION; ESTROGEN ACTIVITY; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DYNAMICS;

ANIMALS; BINDING SITES; DIETHYLSTILBESTROL; DIMERIZATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HUMANS; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PHYTOESTROGENS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; STILBENES; TAMOXIFEN;

EID: 84886231525     PISSN: None     EISSN: 14726807     Source Type: Journal    
DOI: 10.1186/1472-6807-13-27     Document Type: Article

References (57)

1. Concentration of the phytoalexin resveratrol in wine. Siemann EH, Creasy LL, Am J Enol Vitic 1992 43 49 52
2. Inhibition of human LDL oxidation by resveratrol. Frankel EN, Waterhouse AL, Kinsella JE, Lancet 1993 341 1103 1104 (Pubitemid 23114451)
3. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM, Clin Chim Acta 1995 235 207 219 10.1016/0009-8981(95)06045-1 7554275
4. Resveratrol-a boon for treating Alzheimer's disease? Anekonda TS, Brain Res Rev 2006 52 316 326 10.1016/j.brainresrev.2006.04.004 16766037 (Pubitemid 44291807)
5. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM, Science 1997 275 218 220 10.1126/science.275.5297.218 8985016 (Pubitemid 127696281)
6. Suppression of ultraviolet B exposure-mediated activation of NF-kappaB in normal human keratinocytes by resveratrol. Adhami VM, Afaq F, Ahmad N, Neoplasia 2003 5 74 82 12659672 (Pubitemid 36151060)
7. Aggarwal BB, Shishodia S, Resveratrol in health and disease Boca Raton, FL: CRC Press Taylor & Francis Group 2005
8. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Gehm BD, McAndrews JM, Chien PY, Jameson JL, Proc Natl Acad Sci U S A 1997 94 14138 14143 10.1073/pnas.94.25.14138 9391166 (Pubitemid 28009723)
9. Estrogenic/antiestrogenic and sevenging properties of - and (Z)-resveratrol. Basly JP, Marre-Fournier F, Le Bail JC, Habrioux G, Chulia AJ, Life Sci 2000 66 769 777 10.1016/S0024-3205(99)00650-5 10698352 (Pubitemid 30077849)
10. Establishment and its application of a reporter-based screening model for discovering new ligands of estrogen reporter alpha subtypes (in Chinese). Sun Z, Lu QJ, Wen LQ, Guo SM, Chen YY, Liu WJ, Yao Xue Xue Bao 2000 35 747 751 11372440
11. Phytoestrogen regulation of a vitamin D3 receptor promoter and 1,25-dihydroxyvitamin D3 actions in human breast cancer cells. Wietzke JA, Welsh J, J Steroid Biochem Mol Biol 2003 84 149 157 10.1016/S0960-0760(03)00024-4 12710998 (Pubitemid 36514832)
12. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER α Levenson AS, Gehm BD, Pearce ST, Horiguchi J, Simons LA, Ward JE, Jameson JL, Jordan VC, Int J Cancer 2003 104 587 596 10.1002/ijc.10992 12594813 (Pubitemid 36337258)
13. Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. Gehm BD, Levenson AS, Liu H, Lee EJ, Amundsen BM, Cushman M, Jordan VC, Jameson JL, J Ster Biochem & Mol Biol 2004 88 223 234 10.1016/j.jsbmb.2003.12.002 (Pubitemid 38553755)
14. Partial and weak oestrogenicity of the red wine constituent resveratrol: consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects. Ashby J, Tinwell H, Pennie W, Brooks AN, Lefevre PA, Beresford N, Sumpter JP, J Appl Toxicol 1999 19 39 45 10.1002/(SICI)1099-1263(199901/02)19:1<39::AID-JAT534>3.0.CO;2-M 9989476 (Pubitemid 29037630)
15. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors α and β Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM, Endocrinology 2000 141 3657 3667 10.1210/en.141.10.3657 11014220
16. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Mizutani K, Ikeda K, Kawai Y, Yamori Y, Biochem Biophys Res Comm 1998 253 859 863 10.1006/bbrc.1998.9870 9918820 (Pubitemid 29039235)
17. Phytoestrogens act as estrogen agonists in an estrogen-responsive pituitary cell line. Stahl S, Shun TY, Greay WG, Toxicol Appl Pharmacol 1998 152 41 48 10.1006/taap.1998.8500 9772198 (Pubitemid 28498671)
18. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. Lu R, Serrero G, J Cell Physiol 1999 179 297 304 10.1002/(SICI)1097-4652(199906) 179:3<297::AID-JCP7>3.0.CO;2-P 10228948 (Pubitemid 29203154)
19. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM, Cancer Res 2001 61 7456 7463 11606380 (Pubitemid 32995034)
20. Is resveratrol an estrogen agonist in growing rats? Turner RT, Evans GL, Zhang M, Maran A, Sibonga JD, Endocrinology 1999 140 50 54 10.1210/en.140.1.50 9886806 (Pubitemid 29011140)
21. Comparison of the phytohormones genistein, resveratrol and 8-prenylnaringenin as agents for preventing osteoporosis. Sehmisch S, Hammer F, Christoffel J, Deidlova-Wuttke D, Tezval M, Wuttke W, Stuermer KM, Stuermer EK, Planta Med 2008 74 798 801
22. Differential response of immature rat uterine tissue to ethinylestradiol and the red wine constituent resveratrol. Freyberger A, Hartmann E, Hildebrand H, Krotlinger F, Arch Toxicol 2001 74 709 715 10.1007/s002040000186 11218048 (Pubitemid 32208898)
23. Selective oestrogen receptor modulation: molecular pharmacology for the millennium: millennium review 2000. Levenson AS, Jordan VC, Eur J Cancer 1999 35 1628 1639 10.1016/S0959-8049(99)00183-5 10674006 (Pubitemid 30050631)
24. Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor. Levenson AS, Kliakhandler IL, Svoboda KM, Pease KM, Kaiser SA, Ward JE III, Jordan VC, British J Cancer 2002 87 449 456 10.1038/sj.bjc.6600477 (Pubitemid 34983570)
25. Gene expression profiles with activation of the estrogen receptor α-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Levenson AS, Svoboda KM, Pease KM, Kaiser SA, Chen B, Simons LA, Jovanovic BD, Dyck PA, Jordan VC, Cancer Res 2002 62 4419 4426 12154049 (Pubitemid 34827302)
26. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Tsai MJ, O'Malley BW, Annu Rev Biochem 1994 63 451 486 10.1146/annurev.bi.63.070194.002315 7979245 (Pubitemid 24218640)
27. Co-activators and co-repressors in the integration of transcriptional responses. Torchia J, Glass CK, Rosenfeld MG, Curr Opin Cell Biol 1998 10 373 383 10.1016/S0955-0674(98)80014-8 9640539 (Pubitemid 28287049)
28. Structure and specificity of nuclear receptor-coactivator interactions. Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ, Yamamoto KR, Genes Dev 1998 12 3343 3356 10.1101/gad.12.21.3343 9808622 (Pubitemid 28520983)
29. Molecular basis of agonism and antagonism in the oestrogen receptor. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Rngstrom O, Ohman L, Green GL, Gustafsson JA, Carlquist M, Nature 1997 389 753 758 10.1038/39645 9338790 (Pubitemid 27458965)
30. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL, Cell 1998 95 927 937 10.1016/S0092-8674(00)81717-1 9875847 (Pubitemid 29019045)
31. Estrogen receptor transcription and transactivation structure-function relationship in DNA-and ligand-binding domains of estrogen receptors. Ruff M, Gangloff M, Wurtz JM, Moras D, Breast Cancer Res 2000 2 353 359 10.1186/bcr80 11250728 (Pubitemid 32223618)
32. Recognition of resveratrol by the human estrogen receptor-alpha: a molecular modeling approach to understand its biological actions. El-Mowafy AM, Abou-Zeid LA, Edafioghob I, Med Princ Pract 2002 11 86 92 10.1159/000058013 12123109 (Pubitemid 34621675)
33. Differential recognition of resveratrol isomers by the human estrogen receptor-α: molecular dynamics evidence for stereoselective ligand binding. Abou-Zeid LA, El-Mowafy AM, Chirality 2004 16 190 195 10.1002/chir.20007 14770416 (Pubitemid 38295849)
34. In silico design of peptidic inhibitors targeting estrogen receptor alpha dimer interface. Chakraborty S, Cole S, Rader N, King C, Rajnarayanan RV, Biswas PK, Mol Divers 2012 16 441 451 10.1007/s11030-012-9378-x 22752657
35. Insight into estrogen receptor beta-beta and alpha-beta homo and hetero-dimerization: a combined molecular dynamics and sequence analysis study. Chakraborty S, Willett H, Biswas PK, Biophys Chem 2012 170 42 52 23085454
36. Combining docking, molecular dynamics and the linear interaction energy method to predict binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase. Carlsson J, Boukharta L, Aqvist J, J Med Chem 2008 51 2648 2656 10.1021/jm7012198 18410085 (Pubitemid 351620786)
37. Ligand binding affinity prediction by linear interaction energy methods. Hansson T, Marelius J, Aqvist J, J Comput Aided Mol Des 1998 12 27 35 10.1023/A:1007930623000 9570087 (Pubitemid 128513811)
38. Predicting binding modes from free energy calculations. Nervall M, Hanspers P, Carlsson J, Boukharta L, Aqvist J, J Med Chem 2008 51 2657 2667 10.1021/jm701218j 18410080 (Pubitemid 351620787)
39. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method. Lipzig MMV, Laak AMT, Jongejan A, Vermeulen NP, Wamelink M, Geerke D, Meerman JH, J Med Chem 2004 47 1018 1030 10.1021/jm0309607 14761204 (Pubitemid 38176805)
40. Insight into estrogenicity of phytoestrogens using in silico simulation. Sugiyama H, Kumamoto T, Suganami A, Nakanishi W, Sowa Y, Takiguchi M, Ishikawa T, Tamura Y, Biochem Biophys Res Comm 2009 379 139 144 10.1016/j.bbrc.2008.12. 046 19101506
41. Different residues of the human estrogen receptor are involved in the recognition of structurally diverse estrogen and antiestrogens. Ekena K, Weis KE, Katzenellenbogen JA, Katzenellenbogen BS, J Biol Chem 1997 272 5069 5075 10.1074/jbc.272.8.5069 9030571 (Pubitemid 27090061)
42. Phytoestrogens and their human metabolites show distinct agonistic and anatagonistic properties on oestrogen receptor alpha (ERα) and ERβ in human cells. Mueller SO, Simon S, Chae K, Metzker M, Korach KS, Toxicol Sci 2004 80 14 25 10.1093/toxsci/kfh147 15084758 (Pubitemid 38967392)
43. Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, Leitman DC, J Biol Chem 2001 276 17808 17814 10.1074/jbc.M100953200 11279159
44. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptor alpha and beta. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA, Endocrinology 1997 138 863 870 10.1210/en.138.3.863 9048584 (Pubitemid 27089735)
45. Understanding the selectivity of genistein for human estrogen receptor-β using x-ray crystallography and computational methods. Manas ES, Xu ZB, Unwalla RJ, Somers WS, Structure 2004 12 2197 2207 10.1016/j.str.2004. 09.015 15576033 (Pubitemid 39610434)
46. Resveratrol as a phytoestrogen. Gehm BD, Levenson AS, Resveratrol in health and disease Boca Raton, FL: CRC Press Taylor & Francis Group, Aggarwal BB, Shishodia S, 2005 439 464
47. Molecular determinants of tissue selectivity in estrogen receptor modulators. Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, Matsumoto K, Palkowitz AD, Sato M, Termine JD, et al. Proc Natl Acad Sci U S A 1997 94 14105 14110 10.1073/pnas.94.25.14105 9391160 (Pubitemid 28009717)
48. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. Jordan VC, J Natl Cancer Inst 1998 90 967 971 10.1093/jnci/90.13.967 9665143 (Pubitemid 28340436)
49. Tamoxifen: teaching an old drug new tricks? Grainger DJ, Metcalfe JC, Natl Med 1996 2 381 385 10.1038/nm0496-381 (Pubitemid 26191903)
50. Phytoestrogens in health and disease. Davis SK, Dalais FS, Simpson ER, Murkies AL, Recent Prog Horm Res 1999 54 185 210 10548876
51. Automated docking using a Lamarkian genetic algorithm and an empirical binding free energy function. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ, J Comput Chem 1998 19 1639 1662 10.1002/(SICI)1096- 987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B (Pubitemid 128590223)
52. Development and testing of the OPLS all-atom force field on conformational energetic and properties of organic liquids. Jorgensen WL, Rives T, J Am Chem Soc 1988 110 1657 1666 10.1021/ja00214a001
53. GROMACS: a message-passing parallel molecular dynamics implementation. Berendsen HJC, Spoel DVD, Drunen RV, Comp Phys Comm 1995 91 45 56
54. GROMACS 3.0 a package for molecular simulation and trajectory analysis. Lindahl E, Hess B, Spoel DVD, J Mol Model 2001 7 306 317 (Pubitemid 36153547)
55. Unified approach for molecular dynamics and density functional theory. Car R, Parrinello M, Phys Rev Lett 1985 55 2471 2474 10.1103/PhysRevLett.55.2471 10032153
56. LINCS: a linear constraint solver for molecular simulations. Hess B, Bekker H, Berendsen HJC, Fraaije JGEM, J Comp Chem 1997 18 1463 1472 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H (Pubitemid 127637344)
57. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Kabsch W, Sander C, Biopolymers 1983 22 2577 2637 10.1002/bip.360221211 6667333